1. Home
  2. ACGLO vs XERS Comparison

ACGLO vs XERS Comparison

Compare ACGLO & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ACGLO
  • XERS
  • Stock Information
  • Founded
  • ACGLO N/A
  • XERS 2005
  • Country
  • ACGLO Bermuda
  • XERS United States
  • Employees
  • ACGLO 5800
  • XERS N/A
  • Industry
  • ACGLO Property-Casualty Insurers
  • XERS Biotechnology: Pharmaceutical Preparations
  • Sector
  • ACGLO Finance
  • XERS Health Care
  • Exchange
  • ACGLO Nasdaq
  • XERS Nasdaq
  • Market Cap
  • ACGLO N/A
  • XERS 628.7M
  • IPO Year
  • ACGLO N/A
  • XERS 2018
  • Fundamental
  • Price
  • ACGLO $20.51
  • XERS $5.01
  • Analyst Decision
  • ACGLO
  • XERS Strong Buy
  • Analyst Count
  • ACGLO 0
  • XERS 6
  • Target Price
  • ACGLO N/A
  • XERS $6.25
  • AVG Volume (30 Days)
  • ACGLO N/A
  • XERS 2.2M
  • Earning Date
  • ACGLO N/A
  • XERS 05-08-2025
  • Dividend Yield
  • ACGLO N/A
  • XERS N/A
  • EPS Growth
  • ACGLO N/A
  • XERS N/A
  • EPS
  • ACGLO N/A
  • XERS N/A
  • Revenue
  • ACGLO N/A
  • XERS $222,551,000.00
  • Revenue This Year
  • ACGLO N/A
  • XERS $31.75
  • Revenue Next Year
  • ACGLO N/A
  • XERS $21.09
  • P/E Ratio
  • ACGLO N/A
  • XERS N/A
  • Revenue Growth
  • ACGLO N/A
  • XERS 29.88
  • 52 Week Low
  • ACGLO N/A
  • XERS $1.72
  • 52 Week High
  • ACGLO N/A
  • XERS $6.07
  • Technical
  • Relative Strength Index (RSI)
  • ACGLO 45.68
  • XERS 59.63
  • Support Level
  • ACGLO $20.35
  • XERS $4.26
  • Resistance Level
  • ACGLO $20.72
  • XERS $5.28
  • Average True Range (ATR)
  • ACGLO 0.29
  • XERS 0.28
  • MACD
  • ACGLO 0.03
  • XERS 0.09
  • Stochastic Oscillator
  • ACGLO 12.64
  • XERS 78.91

About ACGLO Arch Capital Group Ltd. Depositary Shares Each Representing 1/1000th Interest in a Share of 5.45% Non-Cumulative Preferred Shares Series F

Arch Capital Group Ltd is a Bermuda company that writes insurance and reinsurance with operations in the United States, Canada, Europe, Australia, and the United Kingdom. The business operates through three underwriting segments: insurance, reinsurance, and mortgage. The insurance segment provides specialty risk solutions to clients across various industries. The reinsurance segment provides reinsurance services which cover property catastrophe, property, liability, marine, aviation and space, trade credit and surety, agriculture, accident, life and health, and political risk. The mortgage business provides risk management and risk financing products to the mortgage insurance sectors through platforms in the U.S., Europe and Bermuda.

About XERS Xeris Biopharma Holdings Inc.

Xeris Biopharma Holdings Inc is a biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offer Recorlev for the treatment of Cushing's syndrome, Gvoke for the treatment of severe hypoglycemia, and Keveyis for the treatment of Primary Periodic Paralysis (PPP).

Share on Social Networks: